Neurosurgical Spasticity Treatment: From Lesion to Neuromodulation Procedures by Carrillo-Ruíz, José Damián et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books








Treatment: From Lesion to 
Neuromodulation Procedures
José Damián Carrillo-Ruíz, Jesús Quetzalcoatl Beltran, 
José Rodrigo Carrillo-Márquez, José Luis Navarro-Olvera, 
Luis García, Francisco Villegas-López and Francisco Velasco
Abstract
Spasticity is one of the most important and residual signs after pyramidal and 
para-pyramidal catastrophic lesions after diverse neurological insults, including 
stroke, brain and spine trauma and post-radiation; infection and immunologi-
cal diseases affecting nervous system, between others. Spasticity is normally a 
compensatory motor mechanism that could ameliorate the patients´ disability. 
Nevertheless, disastrous spasticity is described when the extremities force is 
diminished in the affected limbs, or when is impossible to wake o to take objects, 
maximum when hand or foot deformity is exposed. The objective of this chapter is 
centered in the neurosurgical treatment of spasticity, including brain lesions with 
specific targets and the spine with its different modalities. This review shows not 
only the basic aspects in these techniques, but also the option of infusion pumps 
and deep brain stimulation. To close, a proposal is stablished to determinate the 
possible path to treat the spasticity in the future.
Keywords: spasticity, neuroablation, neuromodulation, lesioning neurosurgery, 
motor disorders
1. Introduction
Spasticity is a motor disorder characterized by muscular hypertonia with resis-
tance to passive movement, in a context of hyperexcitability of the stretch reflex. 
This disorder is a component of the upper motor neuron syndrome, an alteration 
where the inhibitory influence of supraspinal structures is lost. Spasticity is an 
important clinical problem frequently found in neurological patients. This condi-
tion is estimated to occur in 17–39% of patients with stroke [1], 37–78% of patients 
with multiple sclerosis [2], 65–78% of patients with spinal cord injury [3], and 90% 
of patients with cerebral palsy [4]. Spasticity could be very disabling for patients 
and its management requires several specialists and different therapeutic options.
If acceptable control of spasticity is not achieved with pharmacological treat-
ment, physical therapy and rehabilitation, surgical procedures are the next treat-
ment option. The goal of surgery in these patients is to decrease the excess muscle 
tone and rebalance agonist and antagonist muscle groups to improve function 
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and limit deformities. To promote a better restoration of function in patients 
with spasticity, it is important to know the functional alterations of this disorder. 
Furthermore, in order to measure the effects on the pathology after some treatment, 
it is necessary to use classifications and scales. In the following sections, the first 
topic to be addressed is the neurophysiological alterations of spasticity and then it 
will be mentioned the scales with which the degree of affection is classified. Later, it 
is going to be described the neurosurgical procedures, both ablative and neuromod-
ulatory, available to compensate for the physiological alterations of this disorder.
2. Spasticity: pathophysiology and classification
2.1 Pathophysiology of spasticity
Muscle tone depends on the intrinsic elasticity/stiffness of the muscle, and this 
in turn is modulated by the nervous system. In physiological conditions, the neural 
circuits in the spinal cord mediate muscle stretch reflexes. These local circuits also 
provide a mechanism to adjust muscle tone from supraspinal structures according 
to physiological requirements. Due to this configuration, lesions in these supraspi-
nal structures or in the descending motor pathways are frequently associated with 
alterations in muscle tone. These alterations may involve an abnormal increase or 
decrease in tone. The most common form of hypertonia is spasticity, which is char-
acterized by a velocity-dependent resistance to passive movement of a joint and its 
associated musculature. A slowly applied stretch in a patient with spasticity causes 
little resistance, but as the speed of the stretch increases, the stretch resistance also 
increases progressively. Thus, spasticity is primarily a phasic phenomenon. An 
active reflex contraction that occurs only during a rapid stretch; when the muscle 
is held in an elongated position, the reflex contraction decreases. However, in some 
cases hypertonia also has a tonic component, for example if reflex contractions 
persist even after the muscle is no longer stretched [5].
In the last years, the pathophysiology of spasticity has been increasingly under-
stood. Stretch reflex hyperactivity was long thought to be caused by overactive 
gamma motor neurons. However, although gamma motor neurons may be overac-
tive in some cases, changes in the background activity of alpha motor neurons 
and interneurons are probably more important. Particularly relevant seem to be 
modifications in the intrinsic properties of motor neurons that generate a sustained 
firing in response to a brief excitatory input. Another mechanism that produces 
spasticity is the strong facilitation of synaptic transmission in the sensory fiber of 
the monosynaptic reflex pathway. In fact, this provides a mechanism for treating 
this disorder. Currently, a relatively common therapeutic procedure favors presyn-
aptic inhibition in the Ia fiber terminals by the intrathecal infusion of baclofen, a 
GABA-B receptor agonist, that blocks neurotransmitter release [5, 6].
2.2 Classification of spasticity
Classifying the severity and distribution of spasticity in each patient is an 
essential element to achieve effective treatment and to observe its response over 
time. The severity of this disorder can range from a focal problem with mild muscle 
stiffness to a severe and painful diffuse spasticity.
Based on its location, spasticity can be classified into Focal, Regional, and 
Generalized. In the first case, a single muscle group or part of the body is affected, in 
regional spasticity, adjacent muscle groups are affected in a region of the body. In the 
patients with generalized spasticity, all or almost all areas of the body are affected [6].
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3. Spasticity assessment
The degree of affection, its evolution over time, and the response to the thera-
peutic options can be evaluated with the use of some scales. There are several 
widely used scales: Ashworth Scale (AS), Modified Ashworth Scale (MAS) and 
Gross Motor Function Classification System (GMFCS). They are formed of differ-
ent points to construct ordinal scale that assess muscle tone. A higher score indi-
cates a more intense spasticity [7].
Moreover, to comprehend correctly the information said before it is necessary 
to understand the meaning of two important concepts: spasticity and spasms. 
Spasticity is “hypertonia that is associated with one or both of the following signs: 
resistance to passive movement that increases with speed of stretch, or when the 
resistance to externally imposed movement rises rapidly above a threshold speed or 
joint angle” [8]. On the other hand, spasms can be defined as “episodes of invol-
untary motor contractions that occur following a lesion of the ascending motor 
pathway” [9]. It is important to mention that spasticity is detrimental to human 
health due to the miscommunication between the brain and the muscles, as a conse-
quence those patients have a diminished quality of life. Spasms can be presented in 
long periods of time that is why problems in the musculoskeletal system can appear, 
affecting mobility and tone of posture.
Bryan Ashworth, in 1964, created a classification in which patients with multiple 
sclerosis could be graded in order of their clinical manifestations, starting to objectivize 
the knowledge of the pathology mentioned before [10]. Between the decades of 1960’s 
to late 1980’s the scale was used by doctors all over the world to help get a more accurate 
diagnose of spasticity, contributing to the progress of science in the field of neurology.
Table 1 shows the classic Ashworth Scale that consist in five different types of 
categories that describe clinical manifestations of spasticity [11].
Furthermore, in 1987 Richard Bohannon’s group added to the scale a category 
“1+” for a more accurate classification regarding clinical manifestations in patients 
with spasticity. Since then, the scientific community has been using this scale of 
measure to add a more specific diagnose in patients that present rigid upper limb 
due to its extension [12]. It is important to mention that both scales, Ashworth and 
Modified Ashworth, are useful in the detection of spasticity and can be helpful to 
objectivize the manifestations of spasticity.
In this image, it can be seen the modifications that Richard Bohannon added to 
the Ashworth Scale (Table 2) [13].
Richard Penn has published several articles concerning spasticity, and also is 
attributed as the creator of a scale that measures the frequency of spasms “Penn 
Spasm Frequency Scale (PSFS)”.
Table 3 shows the different categories of spasms over time to identify character-
istics according to the clinical manifestations [14].
Scale Description
0 No increase in muscle tone.
1 Slight increase in muscle tone, manifested by a catch and release.
2 Marked increase in muscle tone throughout most of the range of motion, but affected 
part(s) easily move.
3 Considerable increase in muscle tone; passive movement difficult.






The objective of the different pharmacological and surgical treatment options is 
to compensate the excitation/inhibition imbalance that occurs in the motoneurons 
of the ventral horn, the common final pathway for motor control. When possible, 
the underlying cause (e.g., tumor, abscess) that could be generated this imbalance 
should be eliminated. It is important to say that spasticity does not always require 
specific treatment. In many cases, spasticity can be helpful in maintaining balance 
and compensate for loss of motor power. Thus, spasticity should be treated when 
excess muscle tone leads to further functional disability, impaired locomotion, 
causes deformities, or induces chronic pain [5].
The different treatment options can be classified according to the location (focal 
vs. general) and duration (temporary vs. permanent) of their therapeutic effect. The 
choice of a treatment is made according to the severity and extent of spasticity and is 
adjusted according to the response and evolution of each patient. In general, surgi-
cal treatment is considered a second-line option, for patients with non-satisfactory 
response with drugs and physical therapy. Neurosurgical treatment options are divided 
into neuroablative and neuromodulatory procedures. The latter allow chemical or 
electrical regulation in the functioning of the neural circuits involved in spasticity. 
Importantly, such neuromodulation is characteristically adjustable and reversible. 
Ablative procedures are fixed and non-reversible. However, they still constitute a viable 
option for many patients, especially in those circumstances in which the use of neu-
romodulation equipment is not available. Figure 1 shows a general algorithm for the 
treatment of a patient with spasticity from its initial assessment to management with 
lesioning procedures. This algorithm is only a general guide, and in each patient the 
treatment should be individualized in the context of a multidisciplinary management.
Scale Description
0 None
1 Lack of spontaneous spasms; vigorous sensory and motor stimulation outcome in 
spasms.
2 Occasional spontaneous spasms occurring es than once per hour.
3 Greater than 1, but less than 10 spontaneous spasms per hour.
4 Greater than 10 spontaneous spasms per hour
Table 3. 
Penn spasm frequency score (PSFS).
Scale Description
0 No increase in muscle tone.
1 Slight increase in muscle tone, manifested by a catch and release.
1+ Slight increase in muscle tone, manifested as a catch, followed through the remainder of the 
range of motion.
2 Marked increase in muscle tone throughout most of the range of motion, but affected part(s) 
easily move.
3 Considerable increase in muscle tone; passive movement difficult.
4 Affected part(s) rigid in flexion or extension.
Table 2. 
Modified Ashworth scale (MAS).
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4.1 Ablative treatment
This treatment modality implies the realization of some injury in certain levels 
of the nervous system that participate in the motor function in order to counteract 
spasticity. These lesions include selective neurotomies, rhizotomies, DREZotomies, 
Figure 1. 
General purpose algorithm for the treatment of spastic patients.
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myelotomies, and supramedular lesions. These procedures should be performed in 
such a way as to reduce excess muscle tone, but preserving residual sensorimotor 
functions and useful muscle tone. In cases of refractory spasticity, including paraple-
gic, hemiplegic or tetraplegic patients, the evolution and severity of the spasticity 
may require neuroablative management. In these cases, the injury procedure must 
be selective, and will be chosen considering the location of the spasticity (Figure 1). 
The characteristics of the most important and useful injuries will be reviewed below.
4.1.1 Selective neurotomy
Peripheral neurotomy was first introduced by Lorenz in 1887 for hip spasticity and 
by Stoffel in 1912 for spasticity in the foot [15]. This procedure consists of selectively 
identifying and injuring one motor nerve bundle that supply the spastic muscles. The 
goal of selective neurotomy is to inhibit the segmental reflex arc and thus limit the level 
of muscle spasticity. Selective neurotomy is indicated in cases of localized spasticity 
in a single or a few muscle groups, both in cases of focal or multifocal spasticity. The 
target nerves are selected according to the spastic region affected. Examples include 
lower subscapular nerve injury for spastic shoulder, median nerve injury for pronation 
spasticity of the upper limb, ulnar neurotomy for spastic wrist flexion with ulnar devia-
tion, obturator nerve lesion in case of hip adduction spasticity, sciatic nerve for knee 
flexion spasticity and tibial neurotomy for equinus or equinovarus spastic foot [16].
The evaluation prior to neurotomy should include nerve blocks with a reversible 
agent such as botulinum toxin. These blocks allow us to observe a therapeutic effect 
previous to neurotomy and to evaluate its usefulness and acceptance. The injury 
must be performed with intraoperative electrophysiological monitoring of the 
nerve to be injured and must include 50–80% of the spastic muscle fibers to expect 
an effective result [5]. The most relevant long-term complications of the neuroto-
mies are allodynia and neuropathic pain. To reduce the probability of the appear-
ance of these adverse effects, it is important to identify and try to avoid sensory 
fibers during the procedure [17].
4.1.2 Selective dorsal rhizotomy
Sir Charles Sherrington, in 1898, showed that stiffness could be abolished 
by dorsal rhizotomy in a feline model with midbrain transection [18]. With this 
background, Otfrid Foerester, in 1913, reported the first dorsal rhizotomy for 
the management of lower limb spasticity in patients with cerebral palsy [19]. 
Rhizotomy consists of the selective section of the dorsal roots of the spinal nerve at 
a specific medullary level. It is thought that its effect is due to the reduction of the 
afferent information of the Ia fibers of the spastic muscle, which would produce 
a decrease in the excitatory input, and an increase in the inhibitory activity of the 
interneurons, to the alpha motoneurons [18, 19]. Dorsal rhizotomy is indicated 
in patients with diffuse or regional spasticity, in patients with spasticity in one or 
two limbs. There is no consensus on the precise selection criteria, but it is most 
frequently performed in paraplegic patients with spasticity in the lower extremities, 
however, it has also been performed successfully in the cervical region in patients 
with spasticity in the upper extremities [20, 21].
The procedure for the lower extremities is usually performed on the posterior 
roots of L1-S2 levels, exposed with a laminectomy or laminoplasty. For spasticity 
of the upper extremities, rhizotomy has been described from C1-C3 levels, not 
sectioning dorsal root of C4 to avoid affecting the diagrammatic function [20, 21]. 
Similar to neurotomies, it is important to perform intraoperative electrophysiologi-
cal mapping to identify the roots that contribute to spasticity. In cases of pediatric 
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cerebral palsy, it has been observed that the patients with the greatest improvement 
are those between 4 and 7 years old and have a preoperative gross motor function 
measure test (GMFM-88) between 65–85% [22]. The most important side effects of 
this procedure are impaired sensation, sphincter dysfunction, cerebrospinal fluid 
fistula, and chronic low back pain [17]. Techniques with more limited and selec-
tive lesions have been tried to improve the results and reduce the probability of the 
appearance of side effects [7].
4.1.3 DREZotomy
This procedure was initially performed by Sindou, in 1972, for the surgical treat-
ment of pain. He observed that this technique also produced important hypotonia in 
the muscles corresponding to the severed medullary segment, and suggested its appli-
cation in cases of spasticity [23, 24]. This surgery is similar to rhizotomy, but the injury 
here is made in the spinal cord, at the Dorsal Root Entry Zone (DREZ). The underlying 
mechanism in this case, is a disruption of Ia afferent inputs to the dorsal horn and a 
disruption of local circuits that contribute to muscle tone [6]. This procedure is indi-
cated in cases of severe regional spasticity, especially those associated with pain and 
poor or no regional function, such as in paraplegic or hemiplegic patients with painful 
hyperspasticity or severe spasms [25, 26]. The surgery, which requires an intradural 
approach and adequate visualization of the posterior surface of the spinal cord, con-
sists of 3-mm deep incision at the dorsolateral sulcus, down to the dorsal horn, follow-
ing its axis. When spasticity is associated with focal dystonia, DREZotomy should be 
more deeply down to the base of the ventral horn [5]. DREZotomy can be performed at 
the C5-C8 medullary levels (at 35° angle) for the management of spasticity in the upper 
extremities or at L1-S2 levels (at 45° angle) for the lower extremity affection. The most 
important complications of this technique are damage to the pyramidal pathway with 
loss of strength and severe hypotonia, so it should be considered in patients with severe 
refractory spasticity who have little residual function in the limb.
4.1.4 Longitudinal myelotomy
Bischof originally described the longitudinal myelotomy in 1951, and it was 
subsequently performed more selectively by Pourpre in 1960, and by Laitinen 
& Singounas in 1971 [8, 27, 28]. This procedure consists of a frontal separation 
between the ventral and dorsal horns at the level of the lumbosacral enlargement. 
The goal of surgery is to interrupt the spinal reflex arc by severing the connec-
tion between the posterior and anterior horns of the spinal cord. Through a T9-L1 
laminectomy or laminoplasty, the procedure is performed at the T11-S2 medullary 
levels. Once the spinal cord is exposed, a posterior longitudinal sagittal incision is 
made deep to the central canal prior to performing a transverse cut using a stylet 
with a right-angled extremity, to separate the ventral and dorsal horns [7]. This 
surgery has been used in the treatment of patients with paraplegia, especially in 
cases with triple flexion and loss of sphincter function [6].
4.1.5 Other procedures
Some stereotaxic procedures in the thalamus and cerebellum have been performed 
for the treatment of spasticity in selected cases. These lesioning procedures include 
ventrolateral thalamotomy, pulvinarotomy, dentatotomy, and lesion of nucleus 
fastigii [29]. Due to the complexity, risks and lack of better effectiveness compared 




On the other hand, orthopedic surgery is another lesioning option. 
Neurosurgical procedures are the first choice for the management of spasticity 
and dystonia, but orthopedic surgery is a complementary surgical option for cases 
in which spasticity persists after neurosurgical treatment. Orthopedic surgery 
can reduce spasticity by releasing or lengthening tendons in the affected region. 
Orthopedic procedures may be indicated primarily when contractures and ankylo-
ses are predominant or like the last option when the deformity is so strong [6].
4.2 Neuromodulation treatment
The classic procedures to treat spasticity are focused to perform lesions or abla-
tive brain, spinal or nerve surgeries, but in recent times it exists the opportunity 
of neuromodulation. This term involved the use of chemical or electric pulses to 
increase or decrease neuron threshold with the main goal to diminish or abolish 
neurological or/and psychiatry symptoms. Neuromodulation is widespread to treat 
neuropathic and phantom pain, movement disorders abnormalities like Parkinson’s 
disease, essential tremor and dystonia; partial and generalized epilepsy; obses-
sive–compulsive disorder, depression or anorexia; motor problems of neurogenic 
bladder, and neurologic deafness and blindness.
In this sense, neuromodulation in spasticity is concerned mainly to the use of 
infusion pumps, treatment acknowledged all over the world. Nevertheless, it exists 
the possibility to utilize electric stimulation in two targets: spinal cord and cerebel-
lar sites to ameliorate the stiffness limb, but is not spread like infusion pumps.
4.2.1 Infusion pumps in spasticity
The next lines are dedicated to resume the infusion pump in the treatment 
of spasticity. It should be said that there is no cure to spasticity, but different 
methods and treatments can be useful. Infusion pumps are generally described as: 
“Complicated electromechanical systems that are used to deliver anesthetic drugs 
with moderate precision” [30]. Regarding neurosciences, different drugs are used 
in order to help patients with spasticity and other similar illnesses, mainly baclofen. 
Since 1984, the usage of infusion pumps with baclofen was proposed by Richard 
Penn due to prior scientific evidence that this chemical could work as an analogue 
of “γ-aminobutyric acid” (GABA) in its B receptor, how it is mentioned [31].
Humans can be treated effectively with intrathecal baclofen to decrease drastically 
the symptoms, and the burden that this illness means. Baclofen is a GABAergic drug 
that is transmitted intrathecally by infusion to the subarachnoid space. Although 
baclofen can be taken orally, the quickness and effectiveness of the chemical is 
decreased in comparison with the utilization of pumps to treat patients with spasticity. 
When taken orally, baclofen can have as a maximum dosage approximately 360 mg per 
day, but when infused intrathecally the dosage reduces to approximately 250–500 μg 
per day. Although, Baclofen is a very effective chemical it also has some repercussions 
like muscle weakness and slowness in walking speed due to the effects that induces, but 
they can be controlled if the dose is adequate for the patient (Table 4) [32].
Overall, the experience of scientists and neurosurgeons using intrathecal 
baclofen can be described as a positive one, but most important good results have 
been shown for patients with spasticity. In Table 4, it can be seen how several 
authors have been using this technique to improve the development of the pathol-
ogy. The former table contains twelve different categories in which all the authors 
present the results obtained by the research. In the “year” column it can be seen 
when the paper was published, and in the “number of patients” the amount of 



















































1 R D Penn 1989 n = 20 19.2(10–33) 70% 4(1) 1.2(0.4) NS NS 100–150 μg/day NS







3 R. Becker 1996 n = 18 13–54 48% 4.5 2.33 PSFS: 2.16 PSFS: 0.94 265 μg/day NS
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2005 n = 138 12 51.24% 4.02(0.92) 1.96(0.78) NS NS 288 μg/d NS
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2016 n = 14 12 86% 3.5 0.5 NS NS 250.5(187.5) μg/
day
NS
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2018 n = 116 64.4(40.7) 50% 4 2 NS NS 152.7(76.8) μg/
day
NS
10 Pedro Videira 
Reis
2019 n = 155 96 (9–132) 75% 4(3–4) 1(1–2) PSFS: 
4(3–4)








was variant, but the tendency as years pass is determined to give the patient a longer 
period between the follow-up in comparison with the older papers. It should be 
said, that when analyzing the Ashworth Scale comparing the preoperatory and the 
post-operatory, results show that using intrathecal baclofen can help reduce drasti-
cally the stiffness to a slight increased muscle tone in the majority of the patients.
Regarding the “dose”, the difference between pediatric and adult treatment 
should be addressed to understand how to apply intrathecal pumps. Some factors in 
children may affect the treatment, that is why there should be a pediatrician involved 
in the process of treating infants in order to apply the correct dosage and time to real-
ize the pump implantation, and do not interfere with their development. In adults, 
it can be said that covering a good dosage is easier because developed organisms can 
receive intrathecal treatments better with doses from 200–600 μg/day. Moreover, due 
to biological variability different patients need more baclofen if they are still showing 
symptoms of spasticity, and less in the case of having problems with movement and 
also muscle weakness; that is why the doctor should be ready to evaluate when to 
adjust the dose of the drug according to patients’ requirements.
Authors with long number of participants tend to have similar results, that is why 
it is important to have a correct number of participants and dose to generate a more 
accurate investigation. The dose of those investigations with more than a hundred 
participants express that the amount of baclofen needed to help a patient can approx-
imately be 220 μg/day as a good reference to start the drug’s usage. Although, none 
of the authors used another drug in their papers it should be said that baclofen is an 
effective chemical that can help patients with spasticity infused intrathecally. Also, it 
is important that doctors have to analyze correctly the dose for a better performance 
of the pump in each individual, and avoid toxicity problems (Figures 2–6).
In the following years, neurosurgeons and their teams have been adding 
information to the methods and the correct usage of this technique, gathering 
approximately 35 years of experience in the field of infusion pumps and the usage 
of baclofen in order to treat spasticity.
4.2.2 Spinal cord stimulation
The first person who used SCS in the treatment of an illness was Shealy when 
he was neurosurgery resident in the 60’s decade. In the 50’s, the original idea was 
emerged after the use of battery connected to cardiac electrodes located in the 
animal’s atrium and modified the myocardial electricity in the treatment of arrhyth-
mias. After an experimental period, the use of a voltaic pile and heart electrodes 
brings the first pacemaker in man, and stablished one of the most important medi-
cal knowledge about implants in the human being until now.
Shealy thought this principle of pacemakers, first in dogs and after in humans, 
could be used in neurologic patients. He took the first patients with uncontrolled 
pain cancer, and he implanted in the spinal cord, a system similar to the cardiac 
patients. The results are the amelioration of pain. Indeed, in this moment Shealy 
was opened the door to Neuromodulation at the neurologic patients [42, 43].
With respect to spasticity, based in the experience of Shealy with SCS for 
pain treatment in 1973, Cook and Wenstein reported one Multiple Sclerosis 
(MS) patient with pain alleviation but with the fortuitous finding that also limb 
spasticity amelioration was presented [44]. In 1976, Illis in UK introduced per-
cutaneous electrodes in two MS patients and peridural space was stimulated and 
improved spasticity [45]. In 1979, Richardson and cols wrote an article with six 
spastic patients, in which spasticity was measure by a scale similar to Ashworth, 
with 36.11% of improvement, and also for first time the article described SCS 
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electric parameters of stimulation (Voltage from 0.5 to 2 V, frequency 33 to 75 
HZ, and pulse width of 100 to 200 μsec) [46]. In 1980, Read and cols reported 
16 MS patients: 9 had spasticity amelioration, 3 without change and 2 had worst 
evolution with increase in spasticity; the total alleviation was 56.25% in the group 
[47]. In the same year, Siegfried showed his experience with originally 26 patients 
using test stimulation before definitive implantation, consisting in percutaneous 
electrodes and depending if the test was positive, they implanted a definitive one. 
Only 11 patients were operated and followed 3 years with amelioration of the spas-
ticity. Best results depending of spinal and partial damage more than cerebral site 
of spasticity. They also used electrophysiological measures like H-reflex to contrast 
the amelioration [48]. Also, in this year, Dimitrijevic showed the results of 11 
patients with spasticity that improved 56.56% after SCS, mainly clonus and EMG 
patterns. In 1985, Barolat-Romana reported 6 spasticity patients with spasms and 
the immediate alleviation after SCS [49]. In 1986, Dimitrijevic and cols studied 59 
patients in which spasticity was reduced in 63% of the group. They found spastic-
ity was controlled better if the electrode was located below the spinal lesion more 
than above, also patients had better results with partial lesion that with complete 
ones [50]. In 1986, the same group with Campos (like the first author) described 
8 patients with minimal function of posterior columns, 90% responded to the 
Figure 2. 
It is shown how baclofen should be injected into the pump’s reserve.
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epidural stimulation [51]. In 1988, Barolat made a clinical trial expanded the initial 
experience to 16 myelopathic subjects with amelioration of spasm and clonus, 
inclusive from one year of follow-up [52]. In 1993, the same group was amplified 
the experience of 509 plates implanted in patients suffered pain and spasticity: 350 
in the whole group, 227 for pain, 105 for motor disturbances (spasms/spasticity 
following spinal cord or cranial trauma, multiple sclerosis, cerebral palsy, spas-
modic torticollis and other motor problems) and 18 patients with both condition: 
pain and spasticity. From these, 3.4% had infection, 1.1% with electrode migration 
and less of 1%, breakage [53]. In the decade of 1990’s it existed poorly advanced 
in this area. In 2000, Pinter and Dimitrijevic discovered that severe spasticity 
in paraplegic patients could improve with the electrode’s position upper to the 
spinal lesion, with frequency of 50–100 Hz, 2–7 Volts and 210 μsec and adapted 
depended of the case [54]. In 2015, Dekopov and Russian team evaluated two 
groups of spasticity patients: Cerebral palsy and spinal cord lesion. SCS amelio-
rated Ashworth scale (58.8%) in cerebral palsy group, but it did not for the spinal 
cord lesion [55].
Figure 3. 
It is demonstrated how the pump should be implanted, so as the stitch used in order to seal the neck of the 
gadget with the catheter.
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4.2.3 Cerebellar stimulation
The understanding of cerebellar human stimulation began in the experiments 
developed in rats, cats, dogs and monkeys. It was based in these antecedent that 
Cooper and cols in 1973 located electrodes on the anterior and posterior surface 
of cerebellum to treat not only spasticity, but seizures also [56–58]. After these 
reports, Cooper and his group contribute significantly to this neuromodulation 
area with different types of articles including implantation technique, clinic 
evolution, surgical complications, neurophysiological changes, psychological 
reactions, between other issues [59–64]. Other groups started to perform CS. In 
1977, Manrique and cols implanted 4 patients with good results to diminished 
spasticity [65], Penn found in some patients diminished spasticity and, in other, 
no changes [66, 67]. Cooper’s work was continued by Davis [68–73] spreading 
the experience in this field. In 2003 and 2007, respectively, Galanda & Horvath 
proposed new insights about CS [74, 75]. In the last decade there has been no 
progress in this area.
Figure 4. 
In the implantation process is important to attach the pump handles to the tissue surrounding the equipment in 




X-ray image shows the infusion pump implanted in the lower part of the left hypochondria. The red arrow 
indicates the catheter connected to the infusion pump, and the tip goes to T-10 level into the subarachnoid space.
Figure 5. 
Post-operatory picture of the pump immediately after the implantation surgery. X-ray image must be taken to 
verify the correct placement of the equipment.
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5. Post-surgery considerations
After any surgical procedure, physical therapy and recovery are very important. 
There is no consensus on the duration and specific type of rehabilitation that should 
be followed. There is great variability in the literature, but some authors recommend 
close follow-up to 3 months after hospital convalescence [16]. The physical therapy 
and rehabilitation protocols must be adapted to each patient, and so should be empa-
thized that is crucial to promote functional improvement after surgical management. 
The results and their functional impact on patients can be seen in variable times, and 
the follow-up should be at least for 6 months. All management and follow-up of the 
patient with spasticity should be carried out, whenever possible, by a multidisci-
plinary team to promote the best results, as well as avoid possible problems [5].
6. Other techniques and targets
Recently, it exists other possibilities to treat spasticity. It is only mentioned to avoid 
extend this review. For one side, magnetic transcranial or spinal stimulation. These 
techniques mean the performance of a coil connected to an electric source to produce 
electromagnetic waves modifying the brain’s plasticity: primary motor cortex or cer-
ebellar cortex are the selected targets; or in an experimental manner in spinal circuitry.
On the other hand, electrical transcutaneous stimulation over the limb or spinal 
cord try to ameliorate also spasticity. It is remarkable that neurosurgical procedures 
in spasticity are the second line of treatment, when rehabilitation maneuvers were 
excluded. After the surgery has been performed the use of physical exercises is 
mandatory. To finish, it should be said that orthopedic procedures must be done 
when the extremities are deformed.
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